BALAXI23.09

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹127 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue-7.7+5.8
EBITDA-77.1-57.3
Net Income-94.3
EPS (adj.)-94.3
Total Assets+8.6+14.2
Total Equity+7.5+11.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.